T
About
Recursion Pharmaceuticals is a pioneering TechBio company that harnesses artificial intelligence and large-scale biological data to transform the drug discovery process. Founded over a decade ago, Recursion built its platform on the insight that AI trained on images of cellular disruptions could decode vast, previously unknown biological space — dramatically reducing the historically high failure rates of traditional pharmaceutical R&D. At the core of its approach is the Recursion Operating System (Recursion OS), an integrated drug discovery and development platform fed by one of the world's largest fit-for-purpose proprietary biological and chemical datasets — over 50 petabytes spanning phenomics, transcriptomics, proteomics, ADME data, and de-identified patient data. An automated wet lab uses robotics and computer vision to run millions of cellular experiments per week, continuously improving the platform through a feedback loop. To power this computational workload, Recursion partnered with NVIDIA to build BioHive-2, biopharma's most powerful supercomputer. The platform has yielded an advanced clinical pipeline targeting aggressive cancers (including solid tumors and B-cell malignancies), rare diseases such as familial adenomatous polyposis, and conditions with high unmet medical need. Recursion collaborates with leading pharmaceutical companies, technology titans, and data partners to accelerate new medicine discovery. Its demonstrated improvements in speed, efficiency, and cost from hit identification to IND-enabling studies position it as one of the top AI drug discovery companies in the industry.
Key Features
- Recursion OS Platform: An integrated AI drug discovery and development operating system that continuously learns from biological experiments to identify targets and design optimized molecules.
- Massive Proprietary Biological Dataset: Over 50 petabytes of fit-for-purpose biological and chemical data spanning phenomics, transcriptomics, proteomics, ADME, and de-identified patient records.
- Automated Wet Lab with Computer Vision: Robotics-driven laboratory infrastructure captures millions of cellular experiments per week, feeding results back into the AI platform in a continuously improving loop.
- BioHive-2 Supercomputer: Built in partnership with NVIDIA, BioHive-2 is biopharma's most powerful supercomputer, enabling large-scale AI model training on complex biological data.
- Advanced Clinical Pipeline: Multiple programs in oncology and rare diseases at various clinical stages, including treatments for solid tumors, B-cell malignancies, and familial adenomatous polyposis.
Use Cases
- AI-driven identification of novel drug targets for aggressive cancers and rare diseases
- Design and optimization of first-in-class and best-in-class therapeutic molecules using generative AI
- Pharmaceutical partnership programs to accelerate pipeline discovery and reduce R&D costs
- Large-scale cellular phenotyping using computer vision to map disease biology
- Multi-omic data integration for precision medicine and biomarker-enriched clinical trial design
Pros
- Unprecedented Scale of Biological Data: With over 50 petabytes of proprietary data and millions of weekly experiments, Recursion operates at a scale that few competitors can match.
- Demonstrated Speed and Cost Improvements: Recursion has shown measurable reductions in time and cost from hit identification to IND-enabling studies compared to traditional pharmaceutical approaches.
- Strong Strategic Partnerships: Collaborations with industry leaders in pharma, NVIDIA for compute, and top-tier data partners reinforce the platform's capabilities and credibility.
- Diverse Clinical Pipeline: Multiple programs across oncology and rare diseases with candidates already in Phase 1 and Phase 1b/2 clinical trials show tangible drug development progress.
Cons
- Enterprise and Partnership Model Only: Recursion's platform is not publicly accessible; access is only available through formal pharmaceutical, technology, or data partnerships.
- Long Drug Development Timelines: Despite AI acceleration, clinical-stage drug programs still require years of trials and regulatory review before potential commercialization.
- Proprietary and Closed Ecosystem: The Recursion OS and its underlying datasets are proprietary, limiting transparency and independent scientific validation of its AI models.
Frequently Asked Questions
What is the Recursion OS?
The Recursion Operating System (Recursion OS) is Recursion's integrated AI drug discovery and development platform. It combines massive biological datasets, machine learning models, and automated wet lab data in a continuously improving feedback loop to identify drug targets and design optimized therapeutic molecules.
How does Recursion use AI for drug discovery?
Recursion trains AI models on images of cellular disruptions and large multi-omic datasets to map unknown biological space, identify novel drug targets, and design highly optimized molecules—reducing the 90% failure rate common in traditional drug discovery.
What therapeutic areas does Recursion focus on?
Recursion currently focuses on oncology (including solid tumors, B-cell malignancies, and HR+ breast cancer) and rare diseases (such as familial adenomatous polyposis and hypophosphatasia), targeting conditions with high unmet medical need.
What partnerships does Recursion have?
Recursion maintains pharmaceutical partnerships with leading drug companies, a technology partnership with NVIDIA (which co-built the BioHive-2 supercomputer), and next-generation data partnerships to continuously enhance its AI capabilities.
How much biological data does Recursion have?
Recursion has generated and aggregated over 50 petabytes of proprietary biological and chemical data, including phenomics, transcriptomics, proteomics, ADME data, and de-identified patient data—among the largest such datasets in the biopharma industry.
